3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Bill Snyder of Vivante Health, Kelly McCormick of UH, and Sean Hunt of Solugen. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to synthetic biology — recently making headlines in Houston innovation.

Bill Snyder, CEO of Vivante Health

Houston startup exec, Bill Snyder, has fresh funding for growth. Photo via vivantehealth.com

Houston-based VivanteHealth closed a $16 million series A funding round, and the fresh funding will support commercial scaling and growth of the company, which is based in Houston's JLABS @ TMC space.

"The Series A financing round represents another pivotal milestone in our mission to improve our member's digestive health and provide outcomes at scale for our enterprise partners," says Bill Snyder, Vivante Health CEO, in a news release. "We are thrilled to partner with premier investors in this latest round of funding that will enable us to continue our rapid growth trajectory and further establish ourselves as the leader in digestive health."

The company is reinventing the way chronic conditions are managed through its digital health program, GIThrive, which equips people with digestive issues with technology, advanced science, and on-demand support. Click here to read more.

Kelly McCormick, managing director of RED Labs

Kelly McCormick wanted to help support UH small business owners. Photo via UH.edu

For years, the University of Houston and Rice University have been working together to support tech startups. Now the pair has announced two new programs — RED Launch and BlueLaunch, respectively — to focus on small businesses. The programs are open to University of Houston and Rice University affiliates who are interested in starting or growing a small business.

"Since inception, RED Labs programming focused mostly on tech entrepreneurship," says Kelly McCormick, managing director of RED Labs. "A few years ago, we began to build out course offerings at the Wolff Center for Entrepreneurship for students interested in small businesses.

"Through those courses, I saw incredible engagement and enthusiasm from students interested in starting a small business, but recognized the need for intensive support beyond classes," she continues.

McCormick says that last summer, UH piloted the first iteration of RED Launch with a small group of UH students, and now UH has brought in Rice to the initiative as well. Click here to read more.

Sean Hunt, co-founder and CTO of Solugen

Solugen has been named among the most innovative companies in the world — and was deemed the No. 1 most innovative manufacturers. Photo via LinkedIn

Houston-based Solugen has ranked second on Fast Company’s 2022 list of the 50 most innovative companies in the world. It also sits at No. 1 on the magazine’s list of the world’s most innovative manufacturers.

Last year, Solugen announced it raised $357 million in a Series C round, catapulting it to “unicorn” status. The Series C round bumped up the startup to a valuation of $1.8 billion, pushing it well past the $1 billion mark required for a unicorn designation.

“This fundraising round allows us to continue expanding the footprint of our Bioforge technology to give industries the products they need to reduce emissions in their existing supply chains, without compromising on performance or economics,” Sean Hunt, co-founder and chief technology officer of Solugen, said in a news release about the $357 million round. Click here to read more.

Vivante Health closed a fresh round of funding. Photo via Getty Images

Houston health tech startup raises $16M series A round

money moves

A Houston-based digital health startup that's targeting solutions for digestive diseases has closed its latest round of funding.

VivanteHealth closed a $16 million series A funding round led by Chicago-based 7wireVentures with contribution from new investors, including Human Capital, Intermountain Ventures, SemperVirens, Elements Health Ventures, and Leaps by Bayer. Additionally, the round saw participation from returning investors FCA Venture Partners, NFP Ventures, Lifeforce Capital, and Big Pi Ventures.

The fresh funding will support commercial scaling and growth of the company, which is based in Houston's JLABS @ TMC space.

"The Series A financing round represents another pivotal milestone in our mission to improve our member's digestive health and provide outcomes at scale for our enterprise partners," says Bill Snyder, Vivante Health CEO, in a news release. "We are thrilled to partner with premier investors in this latest round of funding that will enable us to continue our rapid growth trajectory and further establish ourselves as the leader in digestive health."

The company is reinventing the way chronic conditions are managed through its digital health program, GIThrive, which equips people with digestive issues with technology, advanced science, and on-demand support. Throughout 2021, Vivante Health grew its client base by 400 percent through the addition of key Fortune 500 clients as well as employer healthcare solutions. Through these partnerships, Vivante's potential member base encompasses over 500,000 covered lives, according to the news release.

Around one in four Americans live with a digestive disease, making for a $136 billion market — and Vivante is addressing this need. The company reported that 87 percent of members stated they better managed their digestive symptoms, according to a recent poll, and 83 percent of members said they felt healthier. From a corporate client side, Vivante allows for reductions in direct medical cost, resulting in a 3 to 1 ROI for a large employer organizations.

"The current experience for individuals with GI disorders is at a minimum inadequate and frustrating, and for many, debilitating. To no surprise, over 40 percent of people with a GI condition are dissatisfied with their care," said Robert Garber, Partner at 7wireVentures. "Vivante is on a mission to change that. We are thrilled to partner with the company at a true inflection point in their growth story and accelerate access to a proven, evidence-based model that drastically improves the consumer experience while reducing costs for employers.

In 2020, Vivante raised a $5.8 million series A1. The company was founded in 2016 by serial entrepreneur Kimon Angelides, who recently launched a new business called FemTec Health.

Houston startups have raised millions so far this year. Getty Images

Here's what 6 Houston startups have raised millions of dollars this year so far

VENTURE ADVENTURES

This year is starting strong when it comes to Houston startups receiving funding. From a $125 million raise from Houston's first unicorn to a local fund gathering up $50 million to deploy in mobility startups, Houston funding news has been pretty exciting.

In case you missed some of these headlines, InnovationMap has rounded up these seven deals based on previous reporting. Scroll through to see which Houston startups are catching the eyes — and cashing the checks — of investors.

HighRadius Corp.

Houston-based HighRadius has reported reaching unicorn status following a $125 million raise. Photo via highradius.com

Let's start with the biggest one, shall we? Houston-based HighRadius, an artificial intelligence-powered fintech software company, closed a $125 million raise, which earned it a a new title: Unicorn.

The series B round, which achieved this status for HighRadius, was led by ICONIQ Capital, with participation from existing investors Susquehanna Growth Equity and Citi Ventures, according to a news release from the company.

The company, which offices in West Houston, was founded in 2006 founded in 2006 and employs more than 1,000 people in North America, Europe, and Asia. In November, HighRadius opened an office in Amsterdam. According to the news release, the company will use the funds to further expand its global footprint.

Read the full story here.

Proeza Ventures

Auto Driving Smart Car image

A new venture capital fund based in Houston and Monterrey, Mexico, has raised $50 million to back mobility startups. Hiroshi Watanabe/Getty Images

New fund Proeza Ventures, which is based in Houston and Monterrey, Mexico, reportedly closed its first fund Proeza Ventures I at $50 million. The fund is backed by Grupo Proeza, a Mexican portfolio management company with two global platforms operating in the mobility and agroindustry sectors, according to the fund's website.

With the fund's money, Proenza Ventures will invest in 12 to 15 early or growth-stage startups with solutions or new technology within industrial, smart components, new vehicles, MaaS, and digital data services.

Read the full story here.

Ambyint

oil and gas

Ambyint, which has offices in Calgary and Houston, has secured funding from Houston venture capital firms. Getty Images

Canada-based Ambyint, which has an office in Houston, has closed its $15 million series B funding. Houston-based Cottonwood Venture Partners led the round, and Houston-based Mercury Fund also contributed — as did Ambyint's management team, according to a news release.

The money will be used to grow both its Houston and Calgary, Alberta, offices and expand its suite of software solutions for wells and artificial lift systems. Ambyint's technology pairs artificial intelligence with advanced physics and subject matter expertise to automate processes on across all well types and artificial lift systems.

Read the full story here.

vChain Inc.

Houston-based vChain, creator of CodeNotary, has raised $7 million in a series A financing round. Pexels

Houston-based vChain, which created the CodeNotary Open Source code trust solution, has raised $7 million in a series A funding round. Paris-based Elaia Partners led the investment round, and other contributors include Zug, Switzerland-based Bluwat and Seattle-based Acequia Capital.

The software tool, which is used to ensure code is securely transmitted throughout the entire development to production process, has several platform integrations and works with languages such as JavaScript, Python, Go, Java, and more.

Read the full story here.

Vivante Health

good intestine health intestine Food for bowel Health

Vivante Health, which uses technology and at-home testing to help users treat chronic digestive health issues, has raised $5.8 million. Getty Images

Vivante Health raised $5.8 million in a series A1 round, according to a news release. The round was led by California-based Lifeforce Capital and Athens, Greece-based Big Pi Ventures. Additionally, NFP Ventures, FCA Venture Partners, and Longmont Capital contributed to the round.

With the fresh funds, Vivante will continue to develop its GI health platform, GIThrive. The digital tool has an at-home microbiome test kit for users, as well as a breath tester that monitors food sensitivities. GIThrive also connects users to on-demand support from nutritionists and experts on the GIThrive app.

Read the full story here.

Hitched Inc.

Houston-based Hitched has dug up new investment money from a local private equity firm. Pexels

Hitched Inc. raised $5.5 million in its series A funding led by Houston-based Cottonwood Venture Partners, a growth equity firm that focuses on digital tech solutions in the energy industry.

The company, which was founded in 2018, coordinates the rentals — from hosting and chartering to managing them — all on one centralized platform. Hitched has a catalogue of equipment from generators and cranes to light towers, pumps to forklifts, and the site lists out the cost per day of each piece of machinery.

Read the full story here.

Vivante Health, which uses technology and at-home testing to help users treat chronic digestive health issues, has raised $5.8 million. Getty Images

Digital health startup based in Houston closes $5.8 million round

Money moves

A Houston health technology startup that uses digital solutions and on-demand support to help its users with digestive health has closed a Series A round of funding.

Vivante Health raised $5.8 million in a series A1 round, according to a news release. The round was led by California-based Lifeforce Capital and Athens, Greece-based Big Pi Ventures. Additionally, NFP Ventures, FCA Venture Partners, and Longmont Capital contributed to the round.

"We knew we were onto something when the market responded so positively," says Dr. Kimon Angelides, Vivante Health founder and CEO, in the release, "but support from esteemed, experienced and successful firms like Lifeforce and Big Pi, and the continued strong support from our initial investor partners, give us a very encouraging boost of confidence as we carry out our vision and further develop the GIThrive platform."

With the fresh funds, Vivante will continue to develop its GI health platform, GIThrive. The digital tool has an at-home microbiome test kit for users, as well as a breath tester that monitors food sensitivities. GIThrive also connects users to on-demand support from nutritionists and experts on the GIThrive app.

The startup's Houston headquarters is based out of the Johnson & Johnson Innovation Center, JLabs@TMC, but has offices in Nashville, Chicago, and Athens. Angelides, who honors his Greek heritage by spending a fair about of time in Greece, says in the release how important the Big Pi investment is for him.

"This partnership with Big Pi, a tech-based investment firm who's driven by the desire to support Greek talent, makes perfect sense. What's more, we have partnered with a team who themselves have been very successful entrepreneurs," says Angelides in the release.

Angelides, who has founded three other health tech companies, impressed Big Pi with his entrepreneurial track record and nationwide team

"This is one of those rare investments where the financial upside goes hand in hand with the prospect of radically improving the lives of millions of people across the globe," says Marco Veremis, investment partner with Big Pi, in the release.

Lifeforce Capital has a portfolio of software startups, including Aspire, Cricket Health, Notable Labs, One Medical, and Second Genome, per the news release, and the VC firm is excited for their new addition.

"We were immediately struck by Kim's entrepreneurial passion and big vision," says Sander Duncan, general partner with Lifeforce Capital, in the release. "We are thrilled to work with the Vivante team to build the first platform tackling digestive disease for millions of suffering patients."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


Houston researchers make headway on affordable, sustainable sodium-ion battery

Energy Solutions

A new study by researchers from Rice University’s Department of Materials Science and NanoEngineering, Baylor University and the Indian Institute of Science Education and Research Thiruvananthapuram has introduced a solution that could help develop more affordable and sustainable sodium-ion batteries.

The findings were recently published in the journal Advanced Functional Materials.

The team worked with tiny cone- and disc-shaped carbon materials from oil and gas industry byproducts with a pure graphitic structure. The forms allow for more efficient energy storage with larger sodium and potassium ions, which is a challenge for anodes in battery research. Sodium and potassium are more widely available and cheaper than lithium.

“For years, we’ve known that sodium and potassium are attractive alternatives to lithium,” Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor of Engineering at Rice, said in a news release. “But the challenge has always been finding carbon-based anode materials that can store these larger ions efficiently.”

Lithium-ion batteries traditionally rely on graphite as an anode material. However, traditional graphite structures cannot efficiently store sodium or potassium energy, since the atoms are too big and interactions become too complex to slide in and out of graphite’s layers. The cone and disc structures “offer curvature and spacing that welcome sodium and potassium ions without the need for chemical doping (the process of intentionally adding small amounts of specific atoms or molecules to change its properties) or other artificial modifications,” according to the study.

“This is one of the first clear demonstrations of sodium-ion intercalation in pure graphitic materials with such stability,” Atin Pramanik, first author of the study and a postdoctoral associate in Ajayan’s lab, said in the release. “It challenges the belief that pure graphite can’t work with sodium.”

In lab tests, the carbon cones and discs stored about 230 milliamp-hours of charge per gram (mAh/g) by using sodium ions. They still held 151 mAh/g even after 2,000 fast charging cycles. They also worked with potassium-ion batteries.

“We believe this discovery opens up a new design space for battery anodes,” Ajayan added in the release. “Instead of changing the chemistry, we’re changing the shape, and that’s proving to be just as interesting.”

---

This story originally appeared on EnergyCapitalHTX.com.

View All Listings